RT Journal Article
SR Electronic
T1 Graphene Field Effect Biosensor For Concurrent And Specific Detection Of SARS-CoV-2 And Influenza
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.04.22280705
DO 10.1101/2022.10.04.22280705
A1 Kumar, Neelotpala
A1 Towers, Dalton
A1 Myers, Samantha
A1 Galvin, Cooper
A1 Kireev, Dmitry
A1 Ellington, Andrew
A1 Akinwande, Deji
YR 2022
UL http://medrxiv.org/content/early/2022/10/05/2022.10.04.22280705.abstract
AB The SARS-CoV-2 pandemic has highlighted the need for devices capable of carrying out rapid differential detection of viruses that may manifest similar physiological symptoms yet demand tailored treatment plans. Seasonal influenza may be exacerbated by COVID-19 infections, increasing the burden on healthcare systems. In this work, we demonstrate a technology, based on liquid-gated graphene field-effect transistors, for rapid and ultraprecise detection and differentiation of influenza and SARS-CoV-2 surface protein. The device consists of 4 onboard graphene field-effect electrolyte-gated transistors arranged in a quadruple architecture, where each quarter is functionalized with either antigen-specific antibody or chemically passivated control. The antigen-antibody interaction is dependent on uniform diffusion of virus delivered in low ionic strength phosphate buffer solution, entailing a facile operating procedure, where the user adds a drop of the viral surface protein solution onto the device. Our sensor platform was tested against a range of concentrations of viral surface proteins from both viruses with the lowest tested and detected concentration at ∼50 ag/mL, or 88 zM for COVID-19 and 227 zM for Flu, 5-fold lower than the values reported previously on a similar platform. Unlike the contemporary standard, RT-PCR test, which have a turnaround time of a few hours, the reported graphene biosensor technology has a fast response time of ∼10 seconds enabling rapid diagnosis. Furthermore, the antibodies tested were confirmed to be antigen-specific through cross-reactivity tests. Thus, we have developed a multi-virus, highly sensitive and specific detection tool for rapid diagnostic applications for contemporary, emerging, and future viruses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Science Foundation, Awards #2033846 and #2222907, and the University of Texas ECE departmental research funds. D.A acknowledges the Temple Foundation Endowed Professorship and the Jack Kilby Endowment.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript